Skip to main content

Monte Rosa Therapeutics, Inc.

GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826457

In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.

13F holders, Q3 2025

Institutional positions in Monte Rosa Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
129
+13 vs. Q2 2025
Shares held
60.0M
−2.17M (−3.5%) vs. Q2 2025
Total value
$444.9M
+$164.3M (+58.6%) vs. Q2 2025
New holders
27
35 more added
Sold out
14
41 more reduced

Compare with Q2 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting GLUE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2025: 129 institutions
Q1 2021: 0 institutionsQ2 2021: 48 institutionsQ3 2021: 56 institutionsQ4 2021: 53 institutionsQ1 2022: 52 institutionsQ2 2022: 57 institutionsQ3 2022: 70 institutionsQ4 2022: 66 institutionsQ1 2023: 69 institutionsQ2 2023: 68 institutionsQ3 2023: 71 institutionsQ4 2023: 71 institutionsQ1 2024: 68 institutionsQ2 2024: 75 institutionsQ3 2024: 81 institutionsQ4 2024: 105 institutionsQ1 2025: 106 institutionsQ2 2025: 116 institutionsQ3 2025: 129 institutionsQ4 2025: 161 institutionsQ1 2026: 191 institutionsQ2 2026: 192 institutions
Value heldQ3 2025: $444.9M
Q1 2021: $0Q2 2021: $705.1MQ3 2021: $759.4MQ4 2021: $742.0MQ1 2022: $559.9MQ2 2022: $375.0MQ3 2022: $328.8MQ4 2022: $313.8MQ1 2023: $309.8MQ2 2023: $272.3MQ3 2023: $201.4MQ4 2023: $226.6MQ1 2024: $281.3MQ2 2024: $171.7MQ3 2024: $263.7MQ4 2024: $423.3MQ1 2025: $276.2MQ2 2025: $280.6MQ3 2025: $444.9MQ4 2025: $1.01BQ1 2026: $1.43BQ2 2026: $2.24B
Institutions holding GLUE and their total value by quarter
QuarterHoldersValue
Q2 2026192$2.24B
Q1 2026191$1.43B
Q4 2025161$1.01B
Q3 2025129$444.9M
Q2 2025116$280.6M
Q1 2025106$276.2M
Q4 2024105$423.3M
Q3 202481$263.7M
Q2 202475$171.7M
Q1 202468$281.3M
Q4 202371$226.6M
Q3 202371$201.4M
Q2 202368$272.3M
Q1 202369$309.8M
Q4 202266$313.8M
Q3 202270$328.8M
Q2 202257$375.0M
Q1 202252$559.9M
Q4 202153$742.0M
Q3 202156$759.4M
Q2 202148$705.1M
Q1 20210$0

Institutions, Q3 2025

Shares, value and share of portfolio for each institution holding Monte Rosa Therapeutics, Inc.; share changes are against Q2 2025.

Institutions holding GLUE in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Bridgeway Capital Management, LLC358,850$2.66M0.06%+87,450+32.2%Added
Charles Schwab Investment Management Inc383,268$2.84M0.00%+1,931+0.5%Added
Renaissance Technologies LLC395,733$2.93M0.00%−219,367−35.7%Reduced
Balyasny Asset Management LLC408,540$3.03M0.01%+408,540New
Royal Bank of Canada435,767$3.23M0.00%−34,031−7.2%Reduced
Millennium Management LLC444,939$3.30M0.00%+380,308+588.4%Added
American Century Companies Inc593,394$4.40M0.00%+190,349+47.2%Added
Dimensional Fund Advisors LP632,182$4.68M0.00%+184,020+41.1%Added
Morgan Stanley645,196$4.78M0.00%+74,746+13.1%Added
Silverarc Capital Management, LLC694,942$5.15M0.75%+694,942New
Parkwood LLC708,000$5.25M0.51%00.0%Unchanged
AQR Capital Management LLC717,262$5.31M0.00%−566,680−44.1%Reduced
Northern Trust Corp740,684$5.49M0.00%−20,735−2.7%Reduced
Vestal Point Capital, LP800,000$5.93M0.27%+800,000New
State Street Corp846,773$6.27M0.00%+14,954+1.8%Added
Marshall Wace, LLP902,834$6.69M0.01%+456,754+102.4%Added
Geode Capital Management, LLC1,151,566$8.53M0.00%+27,406+2.4%Added
Alphabet Inc.1,464,015$10.8M0.45%00.0%Unchanged
Aisling Capital Management LP1,472,331$10.9M2.39%00.0%Unchanged
FMR LLC2,812,251$20.8M0.00%+524,217+22.9%Added
Vanguard Group Inc2,988,953$22.1M0.00%−151,557−4.8%Reduced
Suvretta Capital Management, LLC3,360,000$24.9M0.75%00.0%Unchanged
BlackRock, Inc.3,815,133$28.3M0.00%−31,321−0.8%Reduced
Price T Rowe Associates Inc4,637,060$34.4M0.00%−1,688,598−26.7%Reduced
Baker Bros. Advisors LP4,916,095$36.4M0.26%00.0%Unchanged
Versant Venture Management, LLC5,652,922$41.9M19.72%00.0%Unchanged
BVF Inc5,660,132$41.9M1.70%00.0%Unchanged
NEA Management Company, LLC7,692,298$57.0M3.13%00.0%Unchanged
Summit Wealth Group LLC2,002––+2,002New
Avoro Capital Advisors LLC0$00.00%−3,725,000−100.0%Sold out
ExodusPoint Capital Management, LP0$00.00%−109,227−100.0%Sold out
Hillsdale Investment Management Inc.0$00.00%−60,100−100.0%Sold out
Integrated Quantitative Investments LLC0$00.00%−35,400−100.0%Sold out
Stonepine Capital Management, LLC0$00.00%−30,000−100.0%Sold out
UBS Asset Management Americas Inc0$00.00%−24,100−100.0%Sold out
Sherbrooke Park Advisers LLC0$00.00%−21,867−100.0%Sold out
Voya Investment Management LLC0$00.00%−12,958−100.0%Sold out
Lazard Asset Management LLC0$00.00%−10,857−100.0%Sold out
Brighton Jones LLC0$00.00%−10,559−100.0%Sold out
Raymond James Financial Inc0$00.00%−1,200−100.0%Sold out
Caitong International Asset Management Co., Ltd0$00.00%−1,066−100.0%Sold out
Skopos Labs, Inc.0$00.00%−92−100.0%Sold out
GAMMA Investing LLC0$00.00%−80−100.0%Sold out